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The thymus generates a lineage-committed subset of regulatory T-cells (Tregs), best 
identified by the expression of the transcription factor FOXP3. The development of thy-
mus-derived Tregs is known to require high-avidity interaction with MHC-self peptides 
leading to the generation of self-reactive Tregs fundamental for the maintenance of 
self-tolerance. Notwithstanding their crucial role in the control of immune responses, 
human thymic Treg differentiation remains poorly understood. In this mini-review, we will 
focus on the developmental stages at which Treg lineage commitment occurs, and their 
spatial localization in the human thymus, reviewing the molecular requirements, including 
T-cell receptor and cytokine signaling, as well as the cellular interactions involved. An 
overview of the impact of described thymic defects on the Treg compartment will be 
provided, illustrating the importance of these in vivo models to investigate human Treg 
development.
Keywords: human thymus, regulatory T-cells, FOXP3, regulatory T-cell development, human thymic defects, 
primary immunodeficiency
introduction
Regulatory T-cells (Tregs) play a major role in immune homeostasis by preventing or limiting 
T-cell activation, particularly in the context of auto-antigens. Expression of the transcription fac-
tor forkhead box P3 (FOXP3), considered a master regulator of Treg development and function, is 
essential for their role in the maintenance of dominant tolerance [reviewed in Ref. (1)]. Conditions 
where FOXP3 is defective or absent, such as the recessive disorder immune dysregulation, polyen-
docrinopathy, enteropathy, X-linked (IPEX) syndrome, are characterized by aggressive autoimmune 
manifestations that are usually fatal within the first 2 years of life, unless corrected via hematopoietic 
stem-cell transplantation (2–4).
Regulatory T-cells develop primarily in the thymus (thymus-derived Tregs, tTregs), although they 
can also be differentiated in the periphery (peripherally-induced Tregs). The delineation of these 
two populations in the peripheral Treg compartment is difficult due to the lack of specific markers. 
Nevertheless, tTregs are thought to be enriched in self-reactive T-cell receptors (TCRs) and to be 
critical for the maintenance of self-tolerance [reviewed in Ref. (1)]. Despite extensive research on 
tTreg development using murine models in the past 20 years, many questions remain unanswered 
regarding the mechanisms involved in the establishment and maintenance of the tTreg lineage 
[reviewed in Ref. (5, 6)]. Additionally, human tTreg studies are constrained by the limited number 
of tools available. Data have been mainly generated by in vitro manipulation of human thymic tissue 
or in vivo models using mouse/human chimeras [reviewed in Ref. (7)].
In this regard, the information provided by genetic human diseases characterized by thymus-
related disturbances, such as the DiGeorge, the Omenn, and the autoimmune polyendocrinopathy 
candidiasis ectodermal dystrophy (APECED) syndromes, have been instrumental [reviewed in 
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Ref. (8, 9)]. DiGeorge syndrome features athymia in <1% of the 
patients, but in the majority of them the prevailing thymic hypo-
plasia is associated with mild to moderate T-cell lymphopenia, 
and increased incidence of infection and autoimmune diseases 
[reviewed in Ref. (10)]. Alterations in the circulating Treg com-
partment have been consistently reported in DiGeorge syndrome 
(11–13). Notably, a decreased proportion and number of FOXP3+ 
cells in pediatric patients older than 2 years was observed when 
compared to age-matched healthy controls, in direct correlation 
with thymic output, as estimated by the numbers of CD4+ recent 
thymic emigrants (RTEs, defined by the expression of CD31 and 
CD45RA) (12). Omenn syndrome results from hypormorphic 
mutations in severe combined immunodeficiency (SCID)-
causing genes and is associated with the generation of a limited 
pool of T lymphocytes with a restricted repertoire and activated 
phenotype [reviewed in Ref. (8)]. Loss of corticomedullary 
junction and Hassall’s bodies with depletion of autoimmune 
regulator gene (AIRE)-expressing medullary thymic epithelial 
cells (mTECs) and thymic dendritic cells (DCs) were described in 
two Omenn patients, in parallel with a dramatic decrease of Tregs 
in the thymus (14), supporting a role of AIRE-expressing mTEC 
and/or thymic DCs in their differentiation. In agreement, loss-of-
function mutations in the AIRE gene (APECED syndrome) have 
been linked to a defective circulating Treg compartment (15–17). 
Not only is the frequency of naïve/resting Tregs (defined as CD4
+FOXP3+CD45ROnegCD31+) decreased in APECED patients but 
also their levels of FOXP3 expression, function, and repertoire are 
altered, further supporting an abnormal tTreg development in the 
absence of AIRE (16).
A recent study that involved a paired analysis of thymic and 
blood samples in young children (newborns to 1-year-old) 
showed a direct correlation between the size of the two Treg 
compartments, further supporting the importance of the thymus 
for the establishment of the peripheral Treg pool early in life 
(18). Of note, both human and murine RTEs are endowed with 
enhanced potential to convert into peripherally-induced Tregs, 
when compared to their more mature counterparts, implying an 
additional role of the thymus for the setting of the peripheral Treg 
compartment (19). Furthermore, patients with athymia due to 
complete DiGeorge or FOXN1 deficiency have been shown to 
recover the peripheral Treg compartment upon allogeneic thymus 
transplantation, irrespective of the degree of HLA mismatching 
(20–22).
It is vitally important to understand human tTreg development 
in order to devise strategies to manipulate their generation as well 
as their repertoire (23). This mini-review will provide an overview 
of the current knowledge regarding human tTreg development, as 
well as the fundamental questions that remain to be addressed.
Commitment to the Treg Lineage: when?
The human thymic primordium is colonized by T-cell progeni-
tors during the 8th week of gestation, but mature T-cells are only 
observed in the thymus at the 12th to 13th gestational weeks 
(24–26). At this stage, human tTregs can already be found in the 
thymus (27–29). The frequency of fetal human tTregs, identified 
by their elevated expression of the high-affinity IL-2 receptor 
alpha chain (IL-2Rα/CD25), was found to be stable throughout 
gestation (representing 6–7% of total thymocytes) and similar to 
the proportion observed in infant thymuses (28).
Fetal human tTregs already express FOXP3, as assessed at the 
gene expression level, as well as other markers related to their sup-
pressive phenotype, such as cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) and glucocorticoid-induced TNFR-related 
protein (GITR) (27, 28). Moreover, these fetal human tTregs have 
the ability to suppress T-cell proliferation (27, 28).
One question that has been extensively addressed in mice, but 
due to technical limitations only in a few human studies, is when 
and how a thymocyte becomes committed to the Treg lineage. 
The discrete populations that express Treg markers, such as CD25 
and FOXP3, in the human post-natal thymus mainly comprise 
mature CD4 single-positive (CD4SP, CD4+CD8neg) thymocytes, 
but also include CD8 single-positive (CD8SP, CD4negCD8+) and 
double-positive (DP, CD4+CD8+) thymocytes, as well as cells 
in early pre-DP stages (27, 28, 30–36). In agreement, FOXP3+/
CD25+ thymocytes can be found mostly in the medullary region 
of the human thymus, where mature thymocytes localize, with 
rare cells scattered in the cortex (30, 31, 35, 37, 38). The mecha-
nisms that allow for human tTreg commitment to occur are still 
ill-defined.
We and others have reported pre-DP expression of FOXP3, 
namely, at the triple-negative and CD4 immature single-positive 
stages (33, 35) (Table 1). However, the contribution of this popu-
lation to the human tTreg pool remains to be addressed.
Double-positive thymocytes expressing FOXP3 and/or 
CD25 are clearly identified in the human thymus. They addi-
tionally express other Treg function-associated markers, such as 
CTLA-4, CD39, and GITR (27, 28, 36), and exhibit suppressive 
function (32, 36) (Table 1). DP tTregs feature some degree of 
immaturity, as evidenced by the expression of recombination-
activating gene 2 mRNA (34). Moreover, upon stripping of 
surface molecules using pronase, DP tTregs re-acquire both 
CD4 and CD8 at the surface, confirming their bona-fide DP 
status (36). Nevertheless, the majority of human DP tTregs 
express high levels of CD3 and CD27, which are associated with 
positive selection and maturity (27, 36) (Table 1). Importantly, 
DP tTregs are thought to significantly contribute to the CD4SP 
tTreg pool in humans, as predicted by linear regression models 
(36), and formally demonstrated by co-cultures of DP thymo-
cytes with either TEC (36) or mature plasmacytoid (p)DCs 
(38). This observation contrasts with what has been described 
in murine models, where Foxp3 induction, although possible at 
the DP stage (45–47), mostly occurs at the CD4SP stage (48). Of 
note, human CD4SP CD25neg thymocytes are also permissive to 
FOXP3 acquisition (37, 39, 49).
CD4SP tTreg represent the major population of FOXP3+ 
human thymocytes. They phenotypically mirror peripheral 
Tregs and exhibit efficient regulatory function (27, 28, 30, 36, 
41, 43) (Table 1). The contribution of recirculating peripheral 
Tregs to this tTreg compartment is still debatable. It has long 
been proposed that activated T-cells may recirculate back to the 
thymus (50, 51), although this issue is particularly difficult to 
assess in humans. Recently, it was reported that a considerable 
proportion of human CD4SP tTregs may consist of recirculating 
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cells (44). This was based on the observation that approximately 
one-fourth of these cells had lost CD31 and acquired ICOS 
and Tbet expression. Although it is not possible to exclude 
that a fraction of human tTregs may actually represent mature 
recirculating cells, there are some caveats to this interpretation. 
For instance, ICOS is already expressed by tTreg at the DP stage 
(39). Also, the high FOXP3 expression levels found within 
CD4SP ICOS+CD31neg tTregs (44) may reflect their interaction 
with ICOSL expressed on mTECs, as previously described (52). 
Moreover, TREC levels are reportedly comparable between the 
CD4SP CD25+ and CD25neg thymocyte populations, and several 
logs higher that those found in circulating Tregs, supporting that 
the majority of CD4SP tTregs are at the final stage of T-cell devel-
opment (53). Of note, Vbeta usage and spectratyping analyses 
supported that CD4SP tTregs and CD4SP FOXP3neg/CD25neg 
thymocytes have a similarly diverse repertoire (36, 53). To our 
knowledge, the direct comparison of the thymic CD4SP FOXP3+ 
and FOXP3neg repertoires has not been reported. Its assessment 
will be important to clarify this issue since in peripheral cells 
the Treg repertoire has only 24% overlap with conventional CD4 
T-cells (54). Additional studies will be instrumental in deter-
mining the magnitude and role of mature Treg recirculation in 
the human thymus.
Thus, tTreg lineage commitment may occur at various stages 
of human T-cell development.
Commitment to the Treg Lineage: How?
Studies in mice have clearly established the requirement for 
TCR stimulation in Treg lineage commitment [reviewed in 
Ref. (5, 6)]. In humans, technical limitations preclude a direct 
assessment of the role of TCR signaling in tTreg development. 
We and others have shown that human tTreg differentiation 
is associated with markers of positive selection, such as CD69 
and CD27 (27, 28, 34, 36, 42) (Table 1). Moreover, binding sites 
for the TCR downstream targets NFAT and AP1 are present 
within the human FOXP3 promoter that are directly activated 
by TCR stimulation (55). Notably, both DP and CD4SP tTreg 
express CTLA-4 (30, 36), a molecule that in mice was shown to 
be downstream of Nur77, an immediate early gene upregulated 
TABLe 1 | Characterization of human post-natal thymic Tregs.
Markers Pre-DP DP CD4SP CD8SP Reference
FOXP3 + +++ +++ ++ (31, 33, 35, 36, 39, 40)
CD25 − +++ +++ ++ (30, 31, 33, 35, 36, 39, 41)
CTLA-4 + +++ +++ ++ (30, 31, 33, 36, 39, 41, 42)
CD127 −/+ + − − (33–36)
HLA-DR ND ++ + + (36)
CD39 ND ++ ++ + (36)
CD73 ND − − + (36)
CD103 ND + − ++ (36)
ICOS ND ++ ++ + (39, 43, 44)
CD69 ND ++ ++ + (34, 36, 42)
CD27 ND ++ ++ ++ (36, 42)
Ki67 + + −/+ −/+ (36)
Suppressive 
capacity
ND Yes Yes Yes (30–32, 36, 39, 41)
ND, not determined.
by TCR stimulation (56). Indirect evidence that enhanced TCR 
signaling strength may dictate thymocyte commitment into the 
Treg lineage can be further inferred by the increase in CD4SP 
CD25+FOXP3+ thymocyte number in humanized mice treated 
with a superagonist anti-CD28 mAb (57). Moreover, human 
ZAP70-deficient patients present a dramatic decrease in the 
frequency and number of tTregs (58). Interestingly, CD4SP 
CD25+ tTregs were shown to frequently express two functional 
TCRs, in association with enhanced FOXP3 expression, suggest-
ing that dual TCR expression may favor tTreg lineage commit-
ment in humans (40). Overall, available evidence support that 
TCR signaling strength guides thymocyte commitment into 
the Treg lineage in humans, with a predicted impact on their 
self-reactivity.
Several additional signaling pathways and molecular fac-
tors have been implicated in human tTreg differentiation and/
or proliferation, namely JAK3/STAT-5, Notch, CD80/CD86, 
ICOS/ICOSL, CD40/CD40L, thymic stromal lymphopoietin 
(TSLP), as well as the common-gamma chain (γC) cytokines 
interleukin (IL)-2 and -15 (37–39, 49, 52, 59). Watanabe et al. 
demonstrated that TSLP from Hassall’s bodies activate myeloid 
(m)DCs, enabling them to induce tTreg differentiation from 
CD4SP CD25neg thymocytes (37). pDCs are also capable of 
driving CD4SP non-regulatory thymocytes into the human 
Treg lineage, upon response to TSLP (49). Cognate interactions 
between mDCs or pDCs and CD4SP non-regulatory thymo-
cytes are required, as differentiation was impaired by HLA-DR 
blockade (37, 49). Activation of pDCs with anti-CD40L and 
IL-3 also confers on them the capacity to differentiate post-
selection DP CD69hiTCRhi thymocytes into human tTregs (38). 
Additionally, mTECs were shown to promote the survival 
and proliferation of human tTregs in an ICOSL-dependent 
mechanism that required the presence of conventional CD4SP 
cells as source of IL-2 (52). We have recently investigated the 
requirement of γC cytokines in human tTreg development and 
established a critical role for both IL-2 and IL-15 in their line-
age commitment, as well as in tTreg proliferation and survival 
post-selection (39). This study also allowed the identification 
of macrophages and B lymphocytes as main IL-15 producers 
that likely represent two additional thymic antigen-presenting 
cell populations involved in human tTreg differentiation 
(39). In agreement, we found FOXP3+ cells in close vicinity 
of both macrophages and B cells in the human thymus (39). 
Accordingly, B lymphocytes were recently shown to be capable 
of selecting tTreg in mice (60, 61), and the majority of human 
CD4SP tTregs were shown to express CCR8 endowing them 
with the capacity to migrate in response to chemokines pro-
duced by macrophages (30).
As illustrated in Figure  1, the most immature thymocyte 
population that clearly expresses FOXP3, in addition to other 
Treg function-associated markers, such as CD25, CTLA-4, 
and CD39, and displays regulatory function is the cortical 
positively selected DP population (27, 28, 36). The thymic cel-
lular populations and signals mediating their positive selection 
and concomitant recruitment to the Treg lineage may include 
cortical TECs and macrophages, as well as IL-2/IL-15, shown 
by immunohistochemistry to be expressed in the human thymic 
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cortex (39). The DP FOXP3+ thymocyte compartment directly 
correlates with the CD4SP FOXP3+ subset, denoting a precur-
sor–product relationship (36). Upon interaction with activated 
pDCs, post-selection DP FOXP3neg cells may also differentiate 
into Tregs, in a costimulation-dependent manner (38). Medullary 
CD4SP FOXP3neg thymocytes can also acquire FOXP3 expression 
upon cognate interaction with activated pDCs or mDCs, in a 
costimulation- and IL-2-dependent fashion (37, 49). In addition, 
CD4SP FOXP3neg thymocytes may receive appropriate TCR and 
costimulation signals leading to CD25 acquisition and differen-
tiation into tTreg precursors (CD4SP CD25+FOXP3neg cells) (39). 
These precursors can differentiate into tTregs upon exposure to 
IL-2, produced mostly by cycling mature CD4SP thymocytes, or 
IL-15 secreted by macrophages, B lymphocytes, or mTECs (39). 
Whether concomitant TCR, costimulation, and γC cytokine 
signaling also commits medullary CD4SP FOXP3neg thymocytes 
into tTregs, is a possibility remaining to be addressed. Finally, 
CD4SP CD25negFOXP3neg thymocytes TCR-stimulated in the 
presence of costimulation, TGF-β and IL-2/IL-15 signaling can 
also acquire FOXP3 expression and differentiate into CD4SP 
tTreg (19, 39).
FiGURe 1 | Schematic representation of human Treg development 
in the human thymus. DP, double-positive (CD4+CD8+); CD4SP, 
CD4 single-positive (CD4+CD8neg); CD8SP, CD8 single-positive 
(CD8+CD4neg); cTEC, cortical thymic epithelial cell; mTEC, medullary TEC; 
Mac, macrophage; FOXP3, Forkhead box P3; TSLP, thymic stromal 
lymphopoietin.
The Unique Properties of Human  
CD8SP tTregs
In addition to the CD4SP human tTregs, a CD8SP population 
with phenotypic and functional Treg characteristics is present in 
the human thymus. CD8SP human tTregs express several Treg-
associated markers, such as FOXP3, CD25, CTLA-4, and GITR, 
although at lower levels than CD4SP tTregs (31, 36) (Table 1). 
Similarly to CD4SP tTregs, they express very low levels of the 
IL-7 Rα/CD127 molecule (36), and are able to suppress CD4SP 
CD25neg cells in a contact-dependent manner (31) (Table 1). A 
microRNA “signature” of CD8 Tregs has been recently defined in 
cord blood CD8 Treg (62).
Importantly, CD8SP human tTregs were found to express the 
αE chain (CD103) of the αEβ7 integrin (36), a marker associated 
with CD4 Tregs in the periphery (63). CD103 was also expressed 
at the DP stage but was very low within CD4SP thymocytes, sup-
porting a precursor–product relationship between CD103+ DP 
and CD8SP human tTregs (36) (Table 1; Figure 1).
The role of CD103 expression on CD8SP FOXP3+ thymocytes 
remains to be addressed. High expression of E-cadherin, the 
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main ligand of CD103, on mTEC (64) may promote retention of 
CD8 tTregs in the thymic medulla. Furthermore, in an in vitro 
cell adhesion assay, TEC-induced proliferation of CD8SP human 
thymocytes was inhibited by antibodies against E-cadherin or 
CD103, supporting a role for CD103 in CD8SP proliferation 
(64). Although the proliferation of CD8SP CD25+ thymocytes 
was not addressed in this setting, the higher levels of the active 
cell-cycle marker Ki67 found within CD8SP FOXP3+ as com-
pared to CD8SP FOXP3neg thymocytes (36) also support this 
hypothesis.
Despite the low frequency of CD8+ Treg in the steady state, they 
may be of special relevance in pathologic conditions [reviewed in 
Ref. (65, 66)]. CD103 has been associated with T-cell migration 
to mucosal sites (67, 68). In agreement, in the setting of colorectal 
cancer, CD8+FOXP3+CD25+ T-cells were significantly increased 
in peripheral blood and in colorectal cancer tissue, indicating that 
these cells may contribute to tumor immune escape and disease 
progression (69). In addition, studies in macaques have described 
a rapid expansion of CD8+FOXP3+CD25+ Tregs in the blood and 
colorectal mucosa following pathogenic SIV infection (70). An 
increase in the frequency of CD8+ Tregs has also been reported 
in HIV-1-infected patients (70).
In conclusion, a population of CD8+ Tregs is generated in the 
human thymus. A subset of post-selection DP FOXP3+ thymo-
cytes expresses the tissue homing-associated molecule CD103, 
likely giving rise to the CD8SP FOXP3+CD103+ cells found in 
the medulla (Figure 1) (36). This finding supports the possibility 
that CD8+ Tregs egress the thymus expressing markers associ-
ated with mucosal homing, which may explain their very low 
frequency in the blood.
Concluding Remarks
Cumulative evidence supports the existence of different pathways 
of Treg commitment in the human thymus that may occur at 
different stages of thymocyte differentiation. Their physiological 
contribution and the possible implications for the tTreg repertoire 
diversity remain unclear.
Thymus-derived Treg development does not seem to require a 
dedicated antigen-presenting cell population, as studies indicate 
that TECs, mDC, and pDC, as well as macrophages and B cells 
may be involved in tTreg selection. Finally, despite the proposed 
role of TCR signaling strength in human tTreg commitment, it 
has become increasingly clear that γC cytokines, particularly IL-2 
and IL-15, are important mediators of lineage stabilization.
The thymus and specifically tTregs represent important thera-
peutic targets to manipulate tolerance in many clinical settings, 
namely autoimmune diseases, tumor immunity, and transplan-
tation. Furthermore, their targeting is also critical to achieve 
full immunological reconstitution in primary and secondary 
immunodeficiencies and to decrease the morbidity associated 
with hematopoietic stem-cell transplantation. It is therefore of 
utmost importance to further investigate human tTreg develop-
ment, in order to take full-advantage of the current development 
of immune-based therapies.
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